|Awarded On||May 18, 2016|
|Title||Targeted Therapeutic Drug Discovery & Development Program|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Kevin N Dalby|
|Cancer Sites||All Sites|
With the growing appreciation of the molecular pathways underlying different cancers, the new approach of cancer therapeutics is to target specific pathways so that ultimately, we may create rationally-developed combinatorial strategies that circumvent drug resistance. While cancer researchers have identified many clinically important cancer-related targets, the critical challenge in advancing new molecules from ‘discovery’ to pre-clinical testing is lack of access to the specialized resources and multi-disciplinary experiences that are necessary to support the early phase of drug development effort. The goal of the GCC High Throughput Screening Program has been to provide Texas’ researchers...